anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain hair dye able to lower pH in using, suppressing damage of hair or stimulation to scalp, etc., and uniformly dyeing hair in a short time by mixing catalase into oxidation hair dye containing oxidizing dye for hair dyeing and hydrogen peroxide. CONSTITUTION:The subject hair dye is composed of a dye containing oxidizing dye, an oxidizing agent containing hydrogen peroxide and an enzyme agent containing catalase. Preferably the dye component is about 0.05-5%, the hydrogen peroxide is about 0.05-3% and the catalase is about 0.01-100u/ml, especially about 0.1-50u/ml. Said three agents are mixed at using time. The value of pH of said mixture is 4-9, preferably 6-8.5. Value of pH at using time is able to be lowered by using catalase instead of alkali and able to suppress damage of hair or stimulation to scalp. Perfume is able to be added as stimulating smell is small. Hair is able to be uniformly dyed in a short time. Said hair dye is suitable for dyeing of white hair.
Cohort E: will be administered with 0.3 or 1 µg/mm2 ulcer area (total daily dose) as multiple dose (14 days). The dose will be selected based on the SAD results.
Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m\^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m\^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
There is provided by this invention a novel method of treating rheumatoid arthritis in a mammal. The method comprises the steps of obtaining a sample of synovium from the mammal; identifying in said sample T cell receptor variable regions; and administering to said mammal an effective amount of antibodies to at least one of said T cell receptor variable regions or antigenic fragments thereof. The invention further provides a novel method of treating rheumatoid arthritis in a mammal comprising the steps of administering to said mammal an effective amount of antibodies to mammalian T cell receptor variable regions selected from the group consisting of Vα17, Vα1, Vβ12, Vβ14, Vβ17 and Vβ7 and antigenic fragments thereof. The invention further comprises a novel method for immunizing a mammal to prevent the occurrence of rheumatoid arthritis or to treat ongoing rheumatoid arthritis. The method comprises the steps of administering to said mammal mammalian T cell receptor variable regions selected from the group consisting of Vα17, Vα1, Vβ12, Vβ14, Vβ17, Vβ7 and antigenic fragments thereof. Kits comprising mammalian T cell receptor variable regions selected from the group consisting of Vα17, Vα1, Vβ12, Vβ14, Vβ17 and Vβ7 and antigenic fragments thereof or antibodies to said variable regions are also provided by the invention.
A reference radiotherapy treatment plan having a plurality of control points, such as a sequence of gantry angles, aperture leaf positions, and intensity weights, can be adapted during the radiotherapy treatment session. Treatment imaging data of a patient is obtained during the radiotherapy treatment session and used to determine one or more parameters. A current radiotherapy treatment plan is generated based on the one or more parameters. The reference radiotherapy treatment plan for the radiotherapy treatment session is modified during the radiotherapy treatment session by updating one of the plurality of control points of the reference radiotherapy treatment plan with a control point of a current radiotherapy treatment plan. The updated plan is adjusted for patient deformations and movement during the delivery of radiotherapy treatment where the target’s position can vary. This improves the delivery accuracy and efficacy of radiation doses to a patient undergoing radiotherapy treatment and to reduce impact on OARs. Computer implementation can include two computational loops at different rates to generate the at least one parameter.
A hygienic cleaning compsn. for the hands or other parts of the body consists of silica gel, water, emulsifier, solvent and also a very finely powered hard plastic resin (A). A pref. formulation, as a gel or soft paste, comprises 150g Na silicate, 480g water, 150g emulsifying fatty acid; 150g paraffin solvent and 70g (A). This mixt. is treated with H2SO4 to pH8 so as to form silica gel. The compsn. removes all types of soil and scours away adhesive materials which can block the pores. It does not irritate the skin or mucosa and additionally provides softening, disinfectant, fungicidal and sanitising effects.
A topical agent for improving cutaneous scarring (including hypertrophic and keloid scar tissue), wherein the agent is for use in pre-emptive priming of skin at a potential surgical site pre-injury (e.g. from about 3 days prior to surgery). Most preferably, the topical agent is (-)-epigallocatechin-3-gallate (EGCG). Also claimed are compositions (e.g. cream, paste, gel, etc.) comprising the topical agent (e.g. at 2-14 mol.%) for the same use. Also claimed is a surgical dressing containing a topical agent for improving cutaneous scarring at a surgical site, wherein the dressing is for use in pre-operative application to the skin at a site of planned surgery. Further claimed is a non-therapeutic method of enhancing the quality of a scar by topical application of an agent (e.g. EGCG) for improving scar quality, characterised in that said agent is pre-emptively applied to a potential surgical site in advance of surgery. The use of the topical agent may improve the elastin content of the skin.
When liver graft procurements take place in the late afternoon or in the evening, transplantation is often performed at night when alertness and psychomotor abilities may be altered. Our objective was to determine whether liver transplantation performed at night increases severe 90-day postoperative complication rates. In this observational study, we analyzed all consecutive patients who were transplanted between January 1, 2012 and December 31, 2018. Outcomes were compared according to whether all or part of the liver transplantation was performed or not (control group) at late night, i.e., between midnight and 5 a.m. The main outcome was rate of Clavien-Dindo ≥ IIIb complications within 90 days post-transplantation. 790 liver transplantations were analyzed. In a multivariable analysis adjusted for cold ischemic time, late-night procedures required more blood transfusions (P = 0.010) and had higher odds of severe complication occurrence than controls (odds ratio 1.67; 95% CI, [1.10-2.54]). One-year graft and patient survival was similar. We conclude that the organization of liver transplant surgery should be reconsidered to avoid LN surgery as much as can be done. Except to create teams dedicated to night work (which represents a considerable cost), such organization may require safe extension of liver graft preservation times. The alternative could be to extend the use of oxygenated machine perfusion preservation with the unique purpose of safely extending the graft preservation time.
Fifteen healthy volunteers between the ages of 10-18 will be included in this group. No intervention will be applied to this group and they will only be assessed, and their findings obtained from the gait analysis will compare with the patient groups.
The Phyllanthaceae family comprises a diverse range of plants with medicinal, edible, and ornamental value, extensively cultivated worldwide. Polyploid species commonly occur in Phyllanthaceae. Due to the rather complex genomes and evolutionary histories, their speciation process has been still lacking in research. In this study, we generated chromosome-scale haplotype-resolved genomes of two octoploid species (Phyllanthus emblica and Sauropus spatulifolius) in Phyllanthaceae family. Combined with our previously reported one tetraploid (Sauropus androgynus) and one diploid species (Phyllanthus cochinchinensis) from the same family, we explored their speciation history. The three polyploid species were all identified as allopolyploids with subgenome A/B. Each of their two distinct subgenome groups from various species was uncovered to independently share a common diploid ancestor (Ancestor-AA and Ancestor-BB). Via different evolutionary routes, comprising various scenarios of bifurcating divergence, allopolyploidization (hybrid polyploidization), and autopolyploidization, they finally evolved to the current tetraploid S. androgynus, and octoploid S. spatulifolius and P. emblica, respectively. We further discuss the variations in copy number of alleles and the potential impacts within the two octoploids. In addition, we also investigated the fluctuation of metabolites with medical values and identified the key factor in its biosynthesis process in octoploids species. Our study reconstructed the evolutionary history of these Phyllanthaceae species, highlighting the critical roles of polyploidization and hybridization in their speciation processes. The high-quality genomes of the two octoploid species provide valuable genomic resources for further research of evolution and functional genomics.
Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
Despite the clinical and theoretical importance of the negative content in auditory verbal hallucinations (AVHs), little research has been conducted on the topic. A handful of studies suggest that trauma or adverse life events contribute to negative content. The findings are somewhat inconsistent, however, possibly due to methodological limitations. Moreover, only trauma occurring in childhood has been investigated so far. In the present study, we studied the effect of abuse, experienced in either child- or adulthood, and clinical status on negative content of AVHs in four groups of participants that were assessed as part of a large, previously published online survey: Individuals with a psychotic disorder and AVHs (total n = 33), who had experienced abuse (n = 21) or not (n = 12) as well as a group of healthy individuals with AVHs (total n = 53), who had experienced abuse (n = 31) or not (n = 22). We hypothesized that having experienced abuse was associated with a higher degree of negative content. The clinical group collectively reported significantly higher degrees of negative AVHs content compared to the healthy group, but there was no effect of abuse on the degree of negative AVHs content. The presence of AVHs was more common amongst individuals who reported a history of abuse compared to individuals with no history of abuse, both in clinical and healthy participants with AVHs. This implies that at group level, being subjected to traumatic events increases an individual's vulnerability to experiencing AVHs. However, it does not necessarily account for negative content in AVHs.
Acute graft-versus-host disease (aGVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and contributes to high morbidity and mortality. However, our current understanding of the development and progression of aGVHD after allo-HSCT remains limited. To identify the potential biomarkers for the prevention and treatment of aGVHD during the early hematopoietic reconstruction after transplantation, we meticulously performed a comparative analysis of single-cell RNA sequencing data from post-transplant patients with or without aGVHD. Prior to the onset of aGVHD, monocytes in the peripheral blood of patients with aGVHD experienced a dramatic rise and activation on day 21 post-transplantation. This phenomenon is closely aligned with clinical cohort results obtained from blood routine examinations. Furthermore, in vitro co-culture experiments showed that peripheral blood monocytes extracted from patients with aGVHD approximately 21 days post-transplantation induced a significantly higher proliferation rate of allogeneic T cells compared to those from patients without aGVHD. Our study indicates that monocytes could be a crucial early clinical risk factor for the development of aGVHD, and this insight could potentially guide the timing of monitoring efforts, recommending assessments at the pivotal juncture of approximately day 21 post-transplantation, shedding fresh light on the significance of early hematopoietic regeneration in relation to the onset of aGVHD.
Ovarian cancer is the leading cause of death for patients with gynecologic malignancies. In most cases, the disease is diagnosed at an advanced stage and approximately 75% of patients will eventually experience disease recurrence. However, the overall response rates of second-line chemotherapy for recurrent ovarian cancer are only 20-27%. Therefore, it is important to seek alternative agent that can improve the outcome. Apatinib is a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor and it has been approved for the treatment of advanced gastric cancer. The preclinical studies suggest apatinib may be effective in other cancers such as ovarian cancer. Therefore, the purpose of this study is to test the efficacy and safety of the study drug apatinib when combined with a standard treatment, etoposide, for patients with platinum resistant or refractory ovarian cancer.
The present invention relates to a preparation method of xiaokeling for relieving cold phlegm bronchitis cough. Live earthworm is used as a raw material and processed by the method which comprises the four steps of making the earthworm defecate to remove filth, separating the partial coelomic fluid of the earthworm, separating the body of the earthworm from body fluid, and disinfecting and sterilizing the body fluid of the earthworm, so the xiaokeling oral liquid is prepared. The medicine breaks the traditional Chinese medicine viewpoint that earthworms are prevented from being used to treat cold symptoms and treats acute and chronic cold phlegm bronchitis. The method has the advantages of easy raw material acquisition and operation and short production periodicity. The medicine does not need to be matched with other kinds of traditional Chinese medicine when used and has the advantages of quick and favourable effect. The earthworm can be comprehensively utilized in the process of preparation, and the body of the earthworm can be used as fodder.
Colorectal cancer (CRC) is the second most common cancer and the second cause of cancer-related death in Europe. Thirty-one percent of new cases are older than 74 years. The decrease in reserve capacity (i.e., frailty), comorbidity and the surgical treatment imply that the elderly patient is at greater risk of functional decline (reported between 15% and 18% three months after surgery).Up to 50% of those who have experienced functional decline do not recover previous levels of functional independence. The aim of this research is to investigate the effects of a multicomponent physical exercise program on physical function and health-related quality of life (HRQoL) of patients 75 years and older with CRC undergoing surgery. The exercise program focuses on the development of strength, balance, gait ability and inspiratory muscle function of older patients who receive weekly telephone follow-up from cancer diagnosis to 3 months after surgery. Weekly telephone follow-up is provided by an exercise specialist who monitors adherence to the exercise program and insists on its compliance, clarifies any doubt and prescribes exercise progression. Moreover, patients complete a supervised exercise session at baseline, during hospitalization and one month after surgery to ensure correct exercise execution and provide feedback. The investigators expect that ECOOL program will improve physical function and HRQoL of older patients 3 months after surgery and to maintain these benefits up to 6 months after surgery compared with the control group receiving usual care.
Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
The aim of the present study was to determine the associations between the MICB genetic variability and the expression and the risk of development of post-transplant complications after allogeneic hematopoietic stem cell transplantation (HSCT). HSCT recipients and their donors were genotyped for two MICB polymorphisms (rs1065075, rs3828903). Moreover, the expression of a soluble form of MICB was determined in the recipients' serum samples after transplantation using the Luminex assay. Our results revealed a favorable role of the MICB rs1065075 G allele. Recipients with donors carrying this genetic variant were less prone to developing chronic graft-versus-host disease (cGvHD) when compared to recipients without any symptoms of this disease (41.41% vs. 65.38%, p = 0.046). Moreover, the MICB rs1065075 G allele was associated with a lower incidence of cytomegalovirus (CMV) reactivation, both as a donor (p = 0.015) and as a recipient allele (p = 0.039). The MICB rs1065075 G variant was also found to be associated with decreased serum soluble MICB (sMICB) levels, whereas serum sMICB levels were significantly higher in recipients diagnosed with CMV infection (p = 0.0386) and cGvHD (p = 0.0008) compared to recipients without those complications. A protective role of the G allele was also observed for the rs3828903 polymorphism, as it was more frequently detected among donors of recipients without cGvHD (89.90% vs. 69.23%; p = 0.013). MICB genetic variants, as well as serum levels of sMICB, may serve as prognostic factors for the risk of developing cGvHD and CMV infection after allogeneic HSCT.
Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
Up to 30 evaluable patients with a histological diagnosis of prostate cancer with clinical evidence of metastatic disease who are being considered for new therapy or for a change in therapy with a PARP inhibitor, androgen deprivation therapy, and/or chemotherapy as part of their clinical care will be enrolled in this study. A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/ computed tomography (PET/CT) scan will be done prior to the start of a new therapy regimen. PET/CT imaging will be used to evaluate PARP-1 expression in sites of prostate cancer using the investigational radiotracer \[18F\]FTT. This is an observational study in that \[18F\]FTT PET/CT will not be used to direct treatment decisions. While patients and referring physicians will not be blinded to the \[18F\]FTT PET/CT results, treatment decisions will be made by the treating physicians based upon clinical criteria. After injection of \[18F\]FTT patients will undergo a skull base to mid-thigh scan, starting at approximately 60 minutes post injection. PET/CT imaging sessions will include an injection of 12 mCi of \[18F\]FTT intravenously (approximate range for most studies is anticipated to be 8-12 mCi ). of \[18F\] FTT. Data will be collected to evaluate uptake of \[18F\]FTT in sites of prostate cancer, which will be compared with PARP-1 expression in tissue, when available. All evaluable patients may start new therapy following the \[18F\]FTT PET/CT scan. It is expected that due to patient preference and time considerations, approximately 80% will also undergo a second (optional) scan that will be performed approximately 1-21 days after new therapy has started. The second scan is obtained to evaluate whether the initiation of a PARP inhibitor and/or androgen deprivation therapy and/or chemotherapy alters \[18F\] FTT uptake.
An extended reality-based system for dynamic assessment of upper extremity impairments is disclosed. A virtual environment is provided to a user. A target path is received. A sensory stimulus is presented to the user. Three-dimensional position information is determined for one or more body part defining a recorded path. A plurality of motion parameters corresponding to a user response to the stimulus are determined by: comparing the recorded path to the target path, determining a smoothness metric of the recorded path, determining starting coordinates and ending coordinates of the path, determining a first time period from presentation of the sensory stimulus to when motion of the one or more body part begins, and determining a second time period for motion between the starting coordinates and the ending coordinates. At least one index indicative of upper extremity impairment from the plurality of motion parameters.
Isokinetic Exercise program will be applied to the patients. The appropriate modalities will be set on the electrical stimulation device, but the device will not operate. It will be applied for 20 minutes.
Patients randomized to the control group will be given a set of pamphlets explaining symptoms and describing skill-based self-management for symptom management and lifestyle recommendations. Each pamphlet addresses one of the 7 most commonly-reported symptoms (sleep difficulties, fatigue, neuropathy, pain, anxiety, depression, and fear of cancer recurrence) observed in Hong Kong cancer survivors, plus two on lifestyle recommendations (physical activity and healthy diet). All pamphlets are developed based on the self-management framework.
PROBLEM TO BE SOLVED: To obtain an acid hair dye scarcely causing the discoloration by application of a sulfurous acid perming in the acid hair dye using a red dye. SOLUTION: This acid hair dye is prepared by including Red No. 227 as a red dye. The content of the Red No. 227 in the acid hair dye is preferably 0.01-0.5 wt.%. Furthermore, the acid hair dye is preferably used before or after the application of a sulfurous acid perming.
Nuclear factor kappa B (NFκB) is a pathogenic factor in chronic lymphocytic leukemia (CLL) that is not addressed specifically by current therapies. NFκB is activated by inflammatory factors that stimulate toll-like receptors (TLRs) and receptors for interleukin-1 (IL-1) family members. IL-1 is considered a master regulator of inflammation, and IL-1 receptor signaling is inhibited by the IL-1 receptor antagonist anakinra. These considerations suggested that anakinra might have a role in the treatment of CLL. Consistent with this idea, anakinra inhibited spontaneous and TLR7-mediated activation of the canonical NFκB pathway in CLL cells in vitro. However, CLL cells exhibited only weak signaling responses to IL-1 itself, and anakinra was found to inhibit NFκB along with oxidative stress in an IL-1 receptor-independent manner. Anakinra was then administered with minimal toxicity to 11 previously untreated CLL patients in a phase I dose-escalation trial (NCT04691765). A stereotyped clinical response was observed in all patients. Anakinra lowered blood lymphocytes and lymph node sizes within the first month that were associated with downregulation of NFκB and oxidative stress in the leukemia cells. However, inhibition of NFκB was accompanied by upregulation of type 1 interferon (IFN) signaling, c-MYC-regulated genes and proteins, and loss of the initial clinical response. Anakinra increased IFN signaling and survival of CLL cells in vitro that were, respectively, phenocopied by mitochondrial antioxidants and reversed by IFN receptor blocking antibodies. These observations suggest that anakinra has activity in CLL and may be a useful adjunct for conventional therapies as long as compensatory IFN signaling is blocked at the same time.